<http://webisa.webdatacommons.org/422249572>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/422249572>	<http://www.w3.org/ns/prov#value>	"(5) Submission of an amendment to a supplement other than an efficacy or manufacturing supplement will not extend the initial review cycle." .
<http://webisa.webdatacommons.org/422249572>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<fda.gov> .
<http://webisa.webdatacommons.org/prov/182153307>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/422249572> .